Qingming Yang

3.9k citations
62 papers · 2.9k · h-index 20

Impact in

  • Oncology top 1%
    • CAR-T cell therapy research
    • Cancer Immunotherapy and Biomarkers
  • Immunology top 5%
    • Immune Cell Function and Interaction
    • Immunotherapy and Immune Responses

Papers in

Co-authors
Weidong Han (34 shared papers)Yao Wang (20 shared papers)Yelei Guo (18 shared papers)Hanren Dai (15 shared papers)Kaichao Feng (14 shared papers)Zhiqiang Wu (17 shared papers)Meixia Chen (18 shared papers)Chunmeng Wang (17 shared papers)
Journals
Journal of Clinical Oncology (10 papers)Clinical Cancer Research (4 papers)Journal of Hematology & Oncology (3 papers)Signal Transduction and Targeted Therapy (3 papers)Blood (3 papers)
Partner nations
ChinaPhilippinesUnited States

In The Last Decade

Qingming Yang

60 papers receiving 2.8k citations

Peers

Qingming Yang
Comparison fields: 5 of 105
  • Oncology 2.4k
  • Immunology 704
  • Genetics 587
  • Pathology and Forensic Medicine 313
  • Biomedical Engineering 674
Replace Yao Yao with:
Yao Yao China
Tetsushi Kinugasa Japan
Amir Baghbanzadeh Iran
Congcong Zhang China
Sadamu Homma Japan
Inbal Hazan‐Halevy Israel
C. Marcela Díaz‐Montero United States
Ting Wu China
Huan Shi China
Stephan Fricke Germany
Qingming Yang relative to Yao Yao China Yao Yao's profile →
Citations per field
00.5×2×3.5×
Yao Yao · 1×
Citations per year

Countries citing papers authored by Qingming Yang

Since Specialization
Citations

This map shows the geographic impact of Qingming Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingming Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingming Yang more than expected).

Fields of papers citing papers by Qingming Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingming Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingming Yang. The network helps show where Qingming Yang may publish in the future.

Co-authors

The 25 scholars most cited alongside Qingming Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Qingming Yang Line = papers co-authored together Qingming Yang links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Clinical Cancer Research ·Chunmeng Wang, Zhiqiang Wu, Yao Wang, Yelei Guo, Hanren Dai, Xiaohui Wang, Xiang Li, (unknown), Wenying Zhang, Meixia Chen, Yan Zhang, Kaichao Feng, Yang Liu, Su‐Xia Li, Qingming Yang, Weidong Han
2016261
2
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
OncoImmunology ·Yao Wang, Meixia Chen, Zhiqiang Wu, Chuan Tong, Hanren Dai, Yelei Guo, Yang Liu, Jianhua Huang, Haiyan Lv, Can Luo, Kaichao Feng, Qingming Yang, Xiaolei Li, Weidong Han
2018257
3
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
Protein & Cell ·Kaichao Feng, Yang Liu, Yelei Guo, Jingdan Qiu, Zhiqiang Wu, Hanren Dai, Qingming Yang, Yao Wang, Weidong Han
2017240
4
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Journal of Hematology & Oncology ·Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Han Xiao, Yang Liu, Wenying Zhang, Chunmeng Wang, (unknown), Meixia Chen, Qingming Yang, Yao Wang, Weidong Han
2020227
5
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
Blood ·Chuan Tong, (unknown), Yang Liu, Xingyu Ji, Wenying Zhang, Yelei Guo, Han Xiao, Dongdong Ti, Hanren Dai, Chunmeng Wang, Qingming Yang, Wanli Liu, Yao Wang, Zhiqiang Wu, Weidong Han
2020202
6
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
Journal of Hematology & Oncology ·Kaichao Feng, Yelei Guo, Yang Liu, Hanren Dai, Yao Wang, Haiyan Lv, Jianhua Huang, Qingming Yang, Weidong Han
2017202
7
Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Clinical Cancer Research ·Yelei Guo, Kaichao Feng, Yang Liu, Zhiqiang Wu, Hanren Dai, Qingming Yang, Yao Wang, Hejin Jia, Weidong Han
2017196
8
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Cellular and Molecular Immunology ·Zhenguang Wang, Na Li, Kaichao Feng, Meixia Chen, Yan Zhang, Yang Liu, Qingming Yang, Jing Nie, Na Tang, Xingying Zhang, Chen Cheng, Lianjun Shen, Jiaping He, Xun Ye, Wei Cao, Haoyi Wang, Weidong Han
2021177
9
Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
Journal of Clinical Oncology ·Jing Nie, Chunmeng Wang, Yang Liu, Qingming Yang, Qian Mei, Liang Dong, Xiang Li, Jiejie Liu, Wenjing Ku, Yan Zhang, Meixia Chen, Xiaojing An, Lu Shi, Malcolm V. Brock, Jie Bai, Weidong Han
2019154
10
Antioxidant activities of malt extract from barley (Hordeum vulgare L.) toward various oxidative stress in vitro and in vivo
Food Chemistry ·Qingming Yang, Pan Xian-hui, Weibao Kong, Yang Hong, Su Yidan, Zhang Li, Yanan Zhang, Yuling Yang, Lan Ding, Guoan Liu
2009150
11
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
Cytotherapy ·Yang Liu, Yelei Guo, Zhiqiang Wu, Kaichao Feng, Chuan Tong, Yao Wang, Hanren Dai, Fengxia Shi, Qingming Yang, Weidong Han
2020125
12
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
Signal Transduction and Targeted Therapy ·Wenying Zhang, Yao Wang, Yelei Guo, Hanren Dai, Qingming Yang, (unknown), Yan Zhang, Meixia Chen, Chunmeng Wang, Kaichao Feng, Su‐Xia Li, Yang Liu, Fengxia Shi, Can Luo, Weidong Han
2016104
13
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
Journal for ImmunoTherapy of Cancer ·Kaichao Feng, Yang Liu, Yongtian Zhao, Qingming Yang, Liang Dong, Jiejie Liu, Xiang Li, Zhikun Zhao, Qian Mei, Weidong Han
202089
14
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
Leukemia ·(unknown), Yao Wang, Yang Liu, Chuan Tong, Chunmeng Wang, Yelei Guo, Dongdong Ti, Qingming Yang, Shen Qiao, Zhiqiang Wu, Weidong Han
202164
15
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
Journal of Hematology & Oncology ·Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Han Xiao, Qingming Yang, Zhiqiang Wu, Weidong Han
201948
16
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
Journal for ImmunoTherapy of Cancer ·Yang Liu, Chunmeng Wang, Xiang Li, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Malcolm V. Brock, Miao Liu, Qian Mei, Jiejie Liu, Jing Nie, Weidong Han
202148
17
Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
Signal Transduction and Targeted Therapy ·Yao Wang, Chuan Tong, Yuting Lu, Zhiqiang Wu, Yelei Guo, Yang Liu, Jianshu Wei, Chunmeng Wang, Qingming Yang, Weidong Han
202335
18
Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Clinical Cancer Research ·Chunmeng Wang, Yang Liu, Liang Dong, Xiang Li, Qingming Yang, Malcolm V. Brock, Qian Mei, Jiejie Liu, Meixia Chen, Fengxia Shi, Miao Liu, Jing Nie, Weidong Han
202129
19
Anti-oxidative action of ent-kaurene diterpenoids
Research on Chemical Intermediates ·Guoan Liu, Lan Ding, Yang Yan, Hong Yang, Qingming Yang, Hanqing Wang
200626
20
CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
Blood Advances ·Yelei Guo, Chuan Tong, Liping Su, Wenying Zhang, Hejin Jia, Yang Liu, Qingming Yang, Zhiqiang Wu, Yao Wang, Weidong Han
202222

About Qingming Yang

Qingming Yang is a scholar working on Oncology, Pathology and Forensic Medicine, Immunology, Genetics and Surgery, having authored 62 papers that have together received 2.9k indexed citations. Recurring topics across this work include CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (17 papers), Cancer Immunotherapy and Biomarkers (9 papers), Chronic Lymphocytic Leukemia Research (7 papers), Viral-associated cancers and disorders (6 papers), Immune Cell Function and Interaction (6 papers), Virus-based gene therapy research (5 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). The work is most often cited by research in Oncology (2.4k citations), Immunology (704 citations), Genetics (587 citations), Pathology and Forensic Medicine (313 citations) and Biomedical Engineering (674 citations). Qingming Yang has collaborated with scholars based in China, Philippines and United States. Frequent co-authors include Weidong Han, Yao Wang, Yelei Guo, Hanren Dai, Kaichao Feng, Zhiqiang Wu, Meixia Chen, Chunmeng Wang, Yang Liu and Chuan Tong. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Hematology & Oncology, Signal Transduction and Targeted Therapy and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yao YaoBreakdown of academic impact, for papers by Tetsushi KinugasaBreakdown of academic impact, for papers by Amir BaghbanzadehBreakdown of academic impact, for papers by Congcong ZhangBreakdown of academic impact, for papers by Sadamu HommaBreakdown of academic impact, for papers by Inbal Hazan‐HalevyBreakdown of academic impact, for papers by C. Marcela Díaz‐MonteroBreakdown of academic impact, for papers by Ting WuBreakdown of academic impact, for papers by Huan ShiBreakdown of academic impact, for papers by Stephan Fricke